Dr. Michael V. Morabito is a Senior Research Analyst at Chardan covering biotechnology companies, with a focus on diabetes, NASH, and other metabolic diseases. Dr. Morabito joined Chardan in the fall of 2019.
Previously, Dr. Morabito was a Vice President and Senior Analyst in Biotechnology at Credit Suisse, where he covered oncology and metabolic diseases as an analyst following a role as an associate on the US major pharmaceutical team. Prior to that role, Michael served as Scientific Administrator for the Department of Genetic Medicine at Weill Cornell Medical College.
Dr. Morabito has 15 years’ experience in academic research. He conducted his post-doctoral research in the laboratory of Dr. Rudy Leibel at the Naomi Berrie Diabetes Center at Columbia University Medical Center, where he studied the role of the central nervous system in feeding behavior, metabolism and diabetes. For his graduate thesis, Dr. Morabito researched the effects of RNA editing on serotonin signaling and behavior in the laboratory of Dr. Ronald Emeson at Vanderbilt University, where he received his Ph.D. in Neuroscience. Dr. Morabito received his BA in Biology from the University of Virginia, where he researched the molecular mechanisms of biological timing.
We've received your information, and we're processing your request.